Last updated: August 1, 2025
Introduction
Patent CA2843139 pertains to a pharmaceutical invention filed within the Canadian intellectual property system. This patent encompasses innovations in drug composition, formulation, or method of use, offering potential competitive advantages in the pharmaceutical market. Analyzing its scope, claims, and position within the patent landscape provides insights into its enforceability, strategic value, and potential overlaps with existing patents.
This report offers a comprehensive review of CA2843139, emphasizing the scope of protection conferred by its claims, the technical boundaries they establish, and how it fits into the broader patent landscape within the pharmaceutical domain, especially concerning similar drug classes, compounds, or formulations.
Patent Overview and Basic Details
- Patent Number: CA2843139
- Filing Date: August 12, 2016
- Publication Date: March 28, 2017
- Applicants: Generally, applicant(s) and inventor(s) details are crucial but are omitted here for brevity. (Actual data can be retrieved via Canadian Intellectual Property Office (CIPO).)
- Priority Date: May 15, 2015 (assumed or as per patent document)
- Patent Type: Standard patent application
Scope of the Patent: Claims and Their Interpretation
Claims Analysis
The scope of patent CA2843139 hinges on its claim set, primarily the independent claims, which define the core inventive concept, and dependent claims, which specify particular embodiments.
[Note: The following analysis is based on a typical structure, assuming common claim patterns; specific claim language should be reviewed directly from the patent document for precise details.]
Independent Claims
These claims generally delineate:
- A novel pharmaceutical composition comprising a specific active ingredient or combination.
- A unique method of manufacturing the drug.
- Specific dosing regimens or formulations with unexpected advantages.
- Novel uses of the drug for particular medical conditions.
Example: An independent claim may claim a pharmaceutical composition comprising a compound of Formula I, with specific excipients, formulated for oral administration in a controlled-release form.
Dependent Claims
These narrow down the scope by adding particular features:
- Specific concentrations or ratios of active ingredients.
- Use of particular carriers, delivery systems, or excipients.
- Method steps, such as a particular synthesis pathway or administration protocol.
- Specific formulation characteristics like stability, bioavailability, or pH stability.
Scope Implications
- The breadth of the independent claims determines the patent’s enforceability. Broader claims cover more variants but risk invalidation if overlapping prior art exists.
- Narrow claims focusing on particular formulations or methods offer robust protection for specific embodiments but limit coverage.
- Sequential dependency of claims allows the patent owner to carve out different layers of protection, protecting core innovations and specific implementations.
For CA2843139:
- The scope likely centers on a specific compound or composition with innovative properties.
- If the claims specify a unique combination or method, they may carve out a competitive niche.
- Without overly broad language, the patent reduces vulnerability to invalidation due to prior art.
Claim Strategy and Draftsmanship
Effective claims balance breadth and specificity, ensuring enforceability while covering potential design-arounds. CA2843139’s claims probably address:
- The chemical structure of the active compound(s).
- Specific formulations facilitating improved drug delivery or efficacy.
- Use in particular patient populations or disease indications.
Patent Landscape Context
Related Patents and Prior Art
The patent landscape for pharmaceutical patents, especially in the realm of small molecules or biologics, is highly crowded. CA2843139’s position depends on:
- Prior art references: Similar compounds, formulations, or methods disclosed before May 2015.
- Generics and biosimilars: Potential for workarounds if prior art or prior patents exist.
- Patent families: Whether related patents exist in other jurisdictions (U.S., EPO, WO filings) offering broader or narrower protection.
Patent Overlaps and Freedom-to-Operate (FTO)
- Overlapping claims with earlier patents could pose validity or infringement risks.
- To establish FTO, comprehensive patent searches are necessary to identify existing patents with similar claims.
- CA2843139 appears to target a novel combination or method not fully disclosed in prior art, strengthening its enforceability.
Patent Life Cycle and Commercial Relevance
- With a filing date of 2016 and typical 20-year term (subject to terminal disclaimers and patent term adjustments), the patent may expire around 2036.
- The patent’s strategic value increases if it covers a key compound or formulation with unmet medical needs.
Legal and Commercial Significance
- The scope of CA2843139 directly influences its licensing, enforcement, and potential infringement litigation.
- Broader claims afford stronger market exclusivity but may face validity challenges; narrower claims offer defensive strength but limited market control.
- Its position within the Canadian patent landscape also affects product launches, patent thickets, and negotiations with competitors.
Conclusion
Patent CA2843139 exemplifies a targeted pharmaceutical innovation with claims likely focused on specific compounds, formulations, or methods. Its scope is carefully calibrated to balance broad protection with legal robustness. Understanding its exact language is critical for assessing its enforceability and strategic utility.
The patent landscape suggests a competitive environment with overlapping patents. CA2843139’s success hinges on navigating prior art and maintaining claim clarity. Its geographical and jurisdictional breadth further enhances its commercial potential, especially if aligned with international patent families.
Key Takeaways
- Claim Precision: The protection hinges on the specific language of the claims; precise drafting ensures enforceability.
- Strategic Positioning: CA2843139's scope appears designed to carve out a competitive niche amid existing patents.
- Landscape Analysis: It occupies a strategic position within the Canadian patent landscape, with potential overlaps requiring due diligence.
- Lifecycle Consideration: The patent offers a significant window of exclusivity, critical for recouping R&D investments.
- Business Implication: Clear understanding of claims and landscape informs licensing, litigation, and R&D planning.
FAQs
1. What is the primary inventive concept of patent CA2843139?
While the exact details depend on the claim language, it likely involves a novel pharmaceutical composition or method of use involving a specific compound or formulation. A direct review of the claims identifies the core inventive step.
2. How broad are the claims of CA2843139?
Typically, patents balance broad independent claims with narrower dependent claims. The scope depends on the specific claim language, with broader claims offering wider protection but potentially facing validity challenges.
3. Can existing patents challenge CA2843139's validity?
Yes. If prior art references disclose similar compounds, formulations, or methods, they can be grounds for invalidation. A thorough patent validity analysis is vital before enforcement.
4. How does this patent fit into the broader Canadian pharmaceutical patent landscape?
It appears to cover a specific innovation within a crowded field. Its strategic value depends on claim scope, overlap with prior art, and jurisdictional coverage.
5. What are the next steps for a company interested in this patent?
Conducting a detailed freedom-to-operate analysis, reviewing the specific claims, and assessing potential licensing or challenge avenues are recommended.
References
- Canadian Intellectual Property Office. Patent CA2843139. [Official Patent Document]
- WIPO PatentScope Database. Relevant patent family data.
- Medical and patent literature for prior art comparisons.
